A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Jia, Luoqi ^a   Jin, Hongyan ^a   Zhou, Jiayi ^a   Chen, Lianghua ^b   Lu, Yiling ^c   Ming, Yanlin ^b   Yu, Yinhua ^a  

^a FUDAN UNIVERSITY   (China)

^b Xiamen Oversea Chinese Subtropical Plant Introduction Garden   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Cell cycle G2 M arrest; Corilagin; Epithelial mesenchymal transition; Herbal medicine; Ovarian cancer; TGF

Indexed keywords

CORILAGIN; CYCLIN B1; MYT1 PROTEIN; PHOSPHO CDC2 PROTEIN; PROTEIN KINASE B; SMAD PROTEIN; SULFORHODAMINE B; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HERBAL MEDICINE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; OVARY CANCER; PROTEIN MICROARRAY; PROTEIN STABILITY; REVERSE PHASE PROTEIN ARRAY; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; GLUCOSIDES; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; OVARY; PACLITAXEL; PHYLLANTHUS; PHYTOTHERAPY; PLANT EXTRACTS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873709416     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-33     Document Type: Article

References (26)

1. Heintz AP, Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(1):161-192.
2. Liu KC, Lin MT, Lee SS, Chiou JF, Ren S, Lien EJ. Antiviral tannins from two Phyllanthus species. Planta Med 1999, 65:43-46. 10.1055/s-1999-13960, 10083844.
3. Prasad KN, Yang B, Shi J, Yu C, Zhao M, Xue S, Jiang Y. Enhanced antioxidant and antityrosinase activities of longan fruit pericarp by ultra-high-pressure-assisted extraction. J Pharm Biomed Anal 2010, 51:471-477. 10.1016/j.jpba.2009.02.033, 19345542.
4. Hau DK, Zhu GY, Leung AK, Wong RS, Cheng GY, Lai PB, Tong SW, Lau FY, Chan KW, Wong WY, Lam KH, Cheng CH, Cheung F, Chui CH, Gambari R, Fong DW. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine 2010, 18:11-15. 10.1016/j.phymed.2010.09.001, 21036022.
5. Okabe S, Suganuma M, Imayoshi Y, Taniguchi S, Yoshida T, Fujiki H. New TNF-alpha releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, Megusurino-ki. Biol Pharm Bull 2001, 24:1145-1148. 10.1248/bpb.24.1145, 11642320.
6. Fujiki H, Suganuma M, Kurusu M, Okabe S, Imayoshi Y, Taniguchi S, Yoshida T. New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat Res 2003, 523-524:119-125.
7. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D, Yongliang G. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 1999, 18:233-239.
8. Yu YH, Xu FJ, Peng HQ, Fang XJ, Zhao SL, Li Y, Cuevas B, Kuo W-L, Gray JW, Siciliano M, Mills G, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999, 96:214-219. 10.1073/pnas.96.1.214, 15119, 9874798.
9. Colombo R, Batista AN DL, Teles HL, Silva GH, Bomfim GC, Burgos RC, Cavalheiro AJ, da Silva Bolzani V, Silva DH, Pelícia CR, Guimarães FM, Heimberg MC. Validated HPLC method for the standardization of Phyllanthus niruri (herb and commercial extracts) using corilagin as a phytochemical marker. Biomed Chromatogr 2009, 23:573-580. 10.1002/bmc.1155, 19277954.
10. Zhao L, Zhang SL, Tao JY, Pang R, Jin F, Guo YJ, Dong JH, Ye P, Zhao HY, Zheng GH. Preliminary exploration on anti-inflammatory mechanism of Corilagin (beta-1-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-D-glucose) in vitro. Int Immunopharmacol 2008, 8:1059-1064. 10.1016/j.intimp.2008.03.003, 18486919.
11. Kinoshita S, Inoue Y, Nakama S, Ichiba T, Aniya Y. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine 2007, 14:755-762. 10.1016/j.phymed.2006.12.012, 17293097.
12. Santibanez JF, Quintanilla M, Martinez J. Genistein and curcumin block TGF-beta 1-induced u-PA expression and migratory and invasive phenotype in mouse epidermal keratinocytes. Nutr Cancer 2000, 37:49-54. 10.1207/S15327914NC3701_6, 10965519.
13. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002, 8:3512-3519.
14. Singh RP, Dhanalakshmi S, Agarwal R. Phytochemicals as cell cycle modulators-a less toxic approach in halting human cancers. Cell Cycle 2002, 1:156-161.
15. Dangi S, Cha H, Shapiro P. Requirement for phosphatidylinositol-3 kinase activity during progression through S-phase and entry into mitosis. Cell Signal 2003, 15:667-675. 10.1016/S0898-6568(03)00002-0, 12742227.
16. Okumura E, Fukuhara T, Yoshida H, Hanada Si S, Kozutsumi R, Mori M, Tachibana K, Kishimoto T. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat Cell Biol 2002, 4:111-116. 10.1038/ncb741, 11802161.
17. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 2010, 291:59-66. 10.1016/j.canlet.2009.09.017, 19880243.
18. Cheng JC, Auersperg N, Leung PC. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS One 2012, 7:e42436. 10.1371/journal.pone.0042436, 3419689, 22905131.
19. Santin AD, Bellone S, Ravaggi A, Roman J, Smith CV, Pecorelli S, Cannon MJ, Parham GP. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001, 108:804-808.
20. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 2008, 6:695-705. 10.1158/1541-7786.MCR-07-0294, 2927222, 18505915.
21. Alshaker HA, Matalka KZ. IFN-gamma, IL-17 and TGF-beta involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer cell Int 2011, 11:33. 10.1186/1475-2867-11-33, 3195702, 21943203.
22. Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM, Chen L, Hwang JJ. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 2000, 18:493-499. 10.1023/A:1011888126865, 11592306.
23. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-β. Gynecol Oncol 2001, 80:245-253. 10.1006/gyno.2000.6042, 11161867.
24. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003, 3:807-821. 10.1038/nrc1208, 14557817.
25. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003, 112:1116-124. 198530, 14523048.
26. ten Dijke P, Hill CS. New insights into TGF-β-Smad signalling. Trends Biochem Sci 2004, 29:265-73. 10.1016/j.tibs.2004.03.008, 15130563.